Regulatory Aspects of Gene Therapy and Cell Therapy Products - Global

In this review the book Regulatory Aspects of Gene Therapy and Cell Therapy Products offers a practical, global survey of how regulatory authorities evaluate innovative gene therapy and cell therapy medicinal products. It is aimed at developers, translational researchers, and regulatory affairs professionals who need a single reference mapping nonclinical to clinical and licensure pathways across regions. The single biggest reason to buy is its chapterbychapter guidance from experts inside national and international bodies, which makes complex regulatory expectations more accessible for product development planning.

Key Features

• Global regulatory coverage: Chapters authored by international experts present regulatory pathways across North and South America, Europe, and Asia, helping developers compare regional expectations.
• Translational focus: The book walks readers through the application of nonclinical research to translational clinical research, clarifying how early studies inform trial design and licensure strategy.
• Manufacturing considerations: Practical discussion of product manufacturing highlights critical quality and process aspects that affect regulatory acceptance and product consistency.
• Pharmacology and toxicology guidance: Focused insights on safety testing and toxicology approaches tailored to gene and cell therapy platforms support sound preclinical planning.
• Clinical trial design insights: Authors describe clinical trial considerations specific to CT and GT products, assisting sponsors in designing trials that meet regulatory expectations.
• Regulatory guidelines synthesis: The book compiles pertinent mustknow guidelines and regulations to serve as a reference for developers preparing submissions.

Who It's For

The book is best suited for regulatory affairs specialists, translational scientists, clinical trial designers, and biotech developers working on gene therapy or cell therapy products who need a crossjurisdictional perspective. It is also valuable for academic investigators transitioning a therapeutic concept toward clinical development and licensure.

Readers who want stepbystep laboratory protocols, extensive case studies with patientlevel outcomes, or a primer on basic genetics may find the book less appropriate; it is focused on regulatory pathways and product development considerations rather than bench protocols or clinical efficacy reviews.

Pros & Cons

Pros

• Comprehensive international viewpoint that helps compare regulatory expectations between regions.
• Clear linkage of nonclinical research to translational clinical steps, which aids planning and submission strategy.
• Practical coverage of manufacturing, pharmacology, and toxicology elements important to regulators.
• Authored by experts in regulatory bodies, adding authoritative perspective to guidance.

Cons

• Not a methods manual: it does not replace technical laboratory protocols or stepwise manufacturing SOPs.

Specifications

Title	Regulatory Aspects of Gene Therapy and Cell Therapy Products
Series	Advances in Experimental Medicine and Biology, 871
Editors/Authors	Maria Cristina Galli, Mercedes Serabian
Scope	Regulatory pathways and guidelines for gene therapy and cell therapy across multiple regions
Topics covered	Manufacturing, pharmacology, toxicology, clinical trial design, regulatory guidelines
Audience	Regulatory professionals, translational researchers, biotech developers

Our Verdict

Regulatory Aspects of Gene Therapy and Cell Therapy Products is a focused, highvalue reference for professionals navigating regulatory strategy for CT and GT products. Its expertauthored chapters and international scope make it particularly useful for teams seeking to align nonclinical work, manufacturing considerations, and clinical design with regional licensure expectations. It is a worthwhile purchase for developers who need practical regulatory guidance rather than laboratory protocol instruction.

Frequently Asked Questions

Does this book cover multiple regions?
Yes. Chapters provide perspectives on regulatory pathways across North and South America, Europe, and Asia.

Is it suitable for bench scientists?
It is most useful for translational and regulatory work; bench scientists looking for detailed lab protocols should look elsewhere.

Who authored the chapters?
Chapters are written by experts from various national and international regulatory bodies, providing authoritative guidance.